The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - AstraZeneca; Pfizer; Roche/Genentech
Consulting or Advisory Role - Genoptix; GTx; Janssen; Novartis; Radius Health
Research Funding - AstraZeneca; Pfizer (Inst); Roche/Genentech
Other Relationship - Institute of Cancer Research
Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET).
 
Hongchao Pan
No Relationships to Disclose
 
Richard G. Gray
No Relationships to Disclose
 
Christina Davies
No Relationships to Disclose
 
Richard Peto
No Relationships to Disclose
 
Jonas C. S. Bergh
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); Merck (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst)
 
Kathleen I. Pritchard
Honoraria - Amgen; AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Eisai; GlaxoSmithKline; Novartis; Pfizer; Roche
 
Mitch Dowsett
No Relationships to Disclose
 
Daniel F. Hayes
Stock and Other Ownership Interests - InBiomotion; OncImmune
Honoraria - 3rd UK Breast Cancer Meeting, Londong; Lilly
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca (Inst); Janssen Research & Development (Inst); Pfizer (Inst); Puma Biotechnology (Inst)
Patents, Royalties, Other Intellectual Property - Circulating Tumor Cell Capturing Techniques and Devices. Patent No.: US 8,951,484 B2. Date of Patent: Feb. 10, 2015. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Diagnosis and Treatment of Breast Cancer. Patent No. US 8,790,878 B2. Date of Patent: Jul. 29, 2014. Applicant Proprietor: University of Michigan. Dr. Daniel F. Hayes is designated as inventor/co-inventor.; Royalties from licensed technology.; Title: A method for predicting progression free and overall survival at each follow-up timepoint during therapy of metastatic breast cancer patients using circulating tumor cells. Patent no. 05725638.0-1223-US2005008602.